Todd Buck was quoted in The Legal Intelligencer discussing the complexity and uncertainty of the life sciences industry. Todd said that “there’s always a political element to any sort of company, especially with something like pharmaceuticals and technology. You have to have an understanding of the political climate.” Regulatory upheaval and a shaky economic climate are together fueling a growing sense of precariousness about what the future holds. “I think most people right now are nervous about where we’re headed with price caps and things like that,” he said. But he also noted how uncertainty was impacting the transactional side. “Fears of the recession are real in the industry,” he said. “People are being cautious with dealmaking, cautious with making too much investment at this time.” In terms of deals, he has noticed not only are firms proceeding with caution, but that “it tends to be smaller deals rather than the big blockbuster deals that are happening.” 

To read more of this article, click here.